Audentes Therapeutics Growth, Revenue, Number of Employees and Funding
Revenue & Financials
- Audentes Therapeutics's revenue is currently $26.7M per year.
- Audentes Therapeutics received $172.5M in venture funding in October 2018.
- Audentes Therapeutics's revenue per employee is $121735
- Audentes Therapeutics's total funding is $212.5M.
- Audentes Therapeutics has 219 Employees.
- Audentes Therapeutics grew their employee count by 27% last year.
- Audentes Therapeutics currently has 28 job openings.
What Is Audentes Therapeutics?
Audentes is a biotechnology company committed to the development and commercialization of innovative new medicines for people with serious, rare muscle diseases. We are a passionate, energetic team driven by the goals of improving the lives of patients and building a successful business. We take pride in strong, global relationships with the patient, research, and medical communities. If you are interested in learning more about our company, please do not hesitate to contact us.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Advanced Cell D...||$23.9M||166||8%|
|Full Spectrum A...||$5.7M||39||5%|
Audentes Therapeutics News
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Audentes Therapeutics (BOLD – Research Report)
Today, HC Wainwright reiterated its Buy rating on Audentes Therapeutics Inc (NASDAQ:BOLD) with a price target of $44.00. There are 7 Buy
As such, the Zacks rating upgrade for Audentes Therapeutics is essentially a positive comment on its earnings outlook that could have a
Audentes Therapeutics Funding
|2013-07-22||$30.0M||A||OrbiMed Advisors, 5AM Ventures||Article|
|2018-01-24||$172.5M||Undisclosed||BofA Merrill Lynch||Article|
|2018-01-26||$231.4M||Undisclosed||BofA Merrill Lynch||Article|
|2018-10-10||$172.5M||Undisclosed||BofA Merrill Lynch||Article|
Audentes Therapeutics Executive Hires
|2014-03-05||Suyash Prasad||SVP/Chief Medical Officer||Article|
|2017-05-09||John Gray||SVP/Chief Scientific Officer||Article|
|2017-07-19||Fulvio Mavilio||VP scientific affairs, Europe||Article|
|2018-05-09||Natalie Holles||President/Chief Operating Officer||Article|
|2019-01-04||Eric Mosbrooker||SVP/Chief Commercial Officer||Article|